List of antidepressants
This is a complete list of clinically approved prescription antidepressants throughout the world, as well as clinically approved prescription drugs used to augment antidepressants, by pharmacological and/or structural classification. Chemical/generic names are listed first, with brand names in parentheses. All drugs listed are approved specifically for major depressive disorder unless noted otherwise.
- 1 Selective serotonin reuptake inhibitors (SSRIs)
- 2 Serotonin–norepinephrine reuptake inhibitors (SNRIs)
- 3 Serotonin modulators and stimulators (SMS)
- 4 Serotonin antagonists and reuptake inhibitors (SARIs)
- 5 Norepinephrine reuptake inhibitors (NRIs)
- 6 Norepinephrine–dopamine reuptake inhibitors (NDRIs)
- 7 Tricyclic antidepressants (TCAs)
- 8 Tetracyclic antidepressants (TeCAs)
- 9 Monoamine oxidase inhibitors (MAOIs)
- 10 Atypical antipsychotics
- 11 Others
- 12 Adjunctive treatments
- 13 Combination products
- 14 See also
- 15 References
- Citalopram (Celexa)
- Escitalopram (Lexapro, Cipralex)
- Paroxetine (Paxil, Seroxat)
- Fluoxetine (Prozac)
- Fluvoxamine (Luvox, Faverin)
- Sertraline (Zoloft, Lustral)
- Desvenlafaxine (Pristiq)
- Duloxetine (Cymbalta)
- Levomilnacipran (Fetzima)
- Milnacipran (Ixel, Savella)
- Venlafaxine (Effexor)
- Nefazodone (Dutonin, Nefadar, Serzone) – withdrawn/discontinued in most countries
- Trazodone (Desyrel)
Etoperidone may also have been formerly used as an antidepressant, but has been discontinued.
- Reboxetine (Edronax)
- Teniloxazine (Lucelan, Metatone) – also a 5-HT2A receptor antagonist
- Viloxazine (Vivalan)
- Bupropion (Wellbutrin) – weak NDRI, although its dopaminergic actions are controversial; may act as a norepinephrine–dopamine releasing agent (NDRA) alternatively or additionally; also a non-competitive antagonist of nicotinic acetylcholine receptors
Tricyclic antidepressants (TCAs)
- Amitriptyline (Elavil, Endep)
- Amitriptylinoxide (Amioxid, Ambivalon, Equilibrin)
- Clomipramine (Anafranil)
- Desipramine (Norpramin, Pertofrane)
- Dibenzepin (Noveril, Victoril)
- Dimetacrine (Istonil)
- Dosulepin (Prothiaden)
- Doxepin (Adapin, Sinequan)
- Imipramine (Tofranil)
- Lofepramine (Lomont, Gamanil)
- Melitracen (Dixeran, Melixeran, Trausabun)
- Nitroxazepine (Sintamil)
- Nortriptyline (Pamelor, Aventyl)
- Noxiptiline (Agedal, Elronon, Nogedal)
- Opipramol (Insidon)
- Pipofezine (Azafen/Azaphen)
- Protriptyline (Vivactil)
- Trimipramine (Surmontil)
Butriptyline (Evadyne), demexiptiline (Deparon, Tinoran), fluacizine (Phtorazisin), imipraminoxide (Imiprex, Elepsin), iprindole (Prondol, Galatur, Tetran), metapramine (Timaxel), propizepine (Depressin, Vagran), and quinupramine (Kinupril, Kevopril) were also formerly marketed, but have since been discontinued.
Tiazesim (Altinil) and tofenacin (Elamol, Tofacine) are technically not TCAs, but are heterocyclic antidepressants that are very closely related, and similarly to various TCAs, are no longer marketed.
Tetracyclic antidepressants (TeCAs)
- Amoxapine (Asendin)
- Maprotiline (Ludiomil)
- Mianserin (Bolvidon, Norval, Tolvon)
- Mirtazapine (Remeron)
- Setiptiline (Tecipul)
Mianserin, mirtazapine, and setiptiline are also sometimes described as noradrenergic and specific serotonergic antidepressants (NaSSAs).
Monoamine oxidase inhibitors (MAOIs)
Many others, including benmoxin (Neuralex), iproclozide (Sursum), iproniazid (Marsilid), mebanazine (Actomol), nialamide (Niamid), octamoxin (Ximaol), pheniprazine (Catron), phenoxypropazine (Drazine), pivhydrazine (Tersavid), and safrazine (Safra) were used as antidepressants in the past, but have since been discontinued.
Selective for MAO-B
- Selegiline (Eldepryl, Zelapar, Emsam)
Caroxazone (Surodil, Timostenil) was formerly used as an antidepressant, but has been discontinued.
Selective for MAO-A
These drugs are sometimes described as reversible inhibitors of MAO-A (RIMAs).
- Bifemelane (Alnert, Celeport) – RIMA, irreversible inhibitor of MAO-B, and weak NRI
- Amisulpride (Solian) – specifically approved, in low doses, as a monotherapy for dysthymia
- Lurasidone (Latuda) – specifically approved as a monotherapy for depressive episodes in bipolar disorder
- Quetiapine (Seroquel) – specifically approved as a monotherapy for depressive episodes in bipolar disorder
- Agomelatine (Valdoxan) – 5-HT2C receptor antagonist and MT1 and MT2 receptor agonist
- Ketamine (Ketalar) – non-competitive NMDA receptor antagonist – not specifically approved for depression (used off-label)
- Tandospirone (Sediel) – 5-HT1A receptor partial agonist
- Tianeptine (Stablon, Coaxil) – weak and atypical μ-opioid receptor agonist
- Minocycline – Microglia inhibitor (Tetracycline antibiotics) – the overall antidepressant effect size of compared to placebo was -0.78 (95% CI: -0.4 to -1.33, P=0.005) in Meta-analysis. – not specifically approved for depression (used off-label).
- α-Methyltryptamine [αMT] (Indopan) – non-selective serotonin receptor agonist, serotonin–norepinephrine–dopamine releasing agent (SNDRA), and weak RIMA
- Etryptamine [α-Ethyltryptamine (αET)] (Monase) – non-selective serotonin receptor agonist, SNDRA, and weak RIMA
- Indeloxazine (Elen, Noin) – serotonin releasing agent (SRA), NRI, and NMDA receptor antagonist
- Medifoxamine (Clédial, Gerdaxyl) – weak serotonin–dopamine reuptake inhibitor (SDRI) and 5-HT2A and 5-HT2C receptor antagonist
- Oxaflozane (Conflictan) – 5-HT1A, 5-HT2A, and 5-HT2C receptor agonist
- Pivagabine (Tonerg) – unknown/unclear mechanism of action
- Ademetionine [S-Adenosyl-L-methionine (SAMe)] (Heptral, Transmetil, Samyl) – cofactor in monoamine neurotransmitter biosynthesis
- Hypericum perforatum [St. John's Wort (SJW)] (Jarsin, Kira, Movina) – TRPC6 activator, and various other actions
- Oxitriptan [5-Hydroxytryptophan (5-HTP)] (Cincofarm, Levothym, Triptum) – precursor in serotonin biosynthesis
- Rubidium chloride [RbCl] (Rubinorm) – unknown/unclear mechanism of action
- Tryptophan (Tryptan, Optimax, Aminomine) – precursor in serotonin biosynthesis
- Aripiprazole (Abilify) – specifically approved as an adjunct for major depressive disorder
- Brexpiprazole (Rexulti) – specifically approved as an adjunct for major depressive disorder
- Lurasidone (Latuda) – specifically approved for depressive episodes in bipolar disorder
- Olanzapine (Zyprexa) – specifically approved as an adjunct for major depressive disorder
- Quetiapine (Seroquel) – approved as an adjunct for both major depressive disorder and depressive episodes in bipolar disorder
- Risperidone (Risperdal) – not specifically approved as an adjunct for major depressive disorder (used off-label)
- Buspirone (Buspar) – 5-HT1A receptor partial agonist – not specifically approved for depression (used off-label)
- Lithium (Eskalith, Lithobid) – mood stabilizer (mechanism of action unknown/unclear) – not specifically approved for depression (used off-label)
- Thyroxine (T4) – thyroid hormone (thyroid hormone receptor agonist) – not specifically approved for depression (used off-label)
- Triiodothyronine (T3) – thyroid hormone (thyroid hormone receptor agonist) – not specifically approved for depression (used off-label)
Pindolol (Visken), a beta blocker and to a lesser extent 5-HT1A receptor weak partial agonist or functional antagonist, has sometimes been used off-label as an augmentation therapy for SSRIs, but a systematic review and meta-analysis found that it was ineffective.
- Amitriptyline/perphenazine (Etafron) – TCA and typical antipsychotic combination
- Flupentixol/melitracen (Deanxit) – TCA and typical antipsychotic combination
- Olanzapine/fluoxetine (Symbyax) – SSRI and atypical antipsychotic combination – specifically approved as a monotherapy for depressive episodes in bipolar disorder and treatment-resistant depression
- Tranylcypromine/trifluoperazine (Parstelin, Parmodalin, Jatrosom N, Stelapar) – MAOI and typical antipsychotic combination
- Eyding D, Lelgemann M, Grouven U, Härter M, Kromp M, Kaiser T, Kerekes MF, Gerken M, Wieseler B (2010). "Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials". BMJ. 341: c4737. doi:10.1136/bmj.c4737. PMC . PMID 20940209.
- Corp SA, Gitlin MJ, Altshuler LL (2014). "A review of the use of stimulants and stimulant alternatives in treating bipolar depression and major depressive disorder". J Clin Psychiatry. 75 (9): 1010–8. doi:10.4088/JCP.13r08851. PMID 25295426.
- Dell'Osso B, Palazzo MC, Oldani L, Altamura AC (2011). "The noradrenergic action in antidepressant treatments: pharmacological and clinical aspects". CNS Neurosci Ther. 17 (6): 723–32. doi:10.1111/j.1755-5949.2010.00217.x. PMID 21155988.
- Arias HR, Santamaría A, Ali SF (2009). "Pharmacological and neurotoxicological actions mediated by bupropion and diethylpropion". Int. Rev. Neurobiol. 88: 223–55. doi:10.1016/S0074-7742(09)88009-4. PMID 19897080.
- Rampello, Liborio; Nicoletti, Ferdinando; Nicoletti, Francesco (2000). "Dopamine and Depression". CNS Drugs. 13 (1): 35–45. doi:10.2165/00023210-200013010-00004. ISSN 1172-7047.
- Challman TD, Lipsky JJ (2000). "Methylphenidate: its pharmacology and uses". Mayo Clin. Proc. 75 (7): 711–21. doi:10.4065/75.7.711. PMID 10907387.
- Prommer E (2012). "Methylphenidate: established and expanding roles in symptom management". Am J Hosp Palliat Care. 29 (6): 483–90. doi:10.1177/1049909111427029. PMID 22144657.
- Dale E, Bang-Andersen B, Sánchez C (2015). "Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs". Biochem. Pharmacol. 95 (2): 81–97. doi:10.1016/j.bcp.2015.03.011. PMID 25813654.
- Zhang MW, Harris KM, Ho RC (2016). "Is off-label repeat prescription of ketamine as a rapid antidepressant safe? Controversies, ethical concerns, and legal implications". BMC Med Ethics. 17: 4. doi:10.1186/s12910-016-0087-3. PMC . PMID 26768892.
- Rosenblat JD, McIntyre RS (2017-10-28). "Efficacy and tolerability of minocycline for depression: A systematic review and meta-analysis of clinical trials". Journal of Affective Disorders. 227: 219–225. doi:10.1016/j.jad.2017.10.042. PMID 29102836. Retrieved 2017-12-21.
- Gian F. Placidi; Liliana Dell'Osso; Giuseppe Nistico; Hagop S. Akiskal (6 December 2012). Recurrent Mood Disorders: New Perspectives in Therapy. Springer Science & Business Media. pp. 293–. ISBN 978-3-642-76646-6.
- Thase ME (2016). "Adverse Effects of Second-Generation Antipsychotics as Adjuncts to Antidepressants: Are the Risks Worth the Benefits?". Psychiatr. Clin. North Am. 39 (3): 477–86. doi:10.1016/j.psc.2016.04.008. PMID 27514300.
- Liu Y, Zhou X, Zhu D, Chen J, Qin B, Zhang Y, Wang X, Yang D, Meng H, Luo Q, Xie P (2015). "Is pindolol augmentation effective in depressed patients resistant to selective serotonin reuptake inhibitors? A systematic review and meta-analysis". Hum Psychopharmacol. 30 (3): 132–42. doi:10.1002/hup.2465. PMID 25689398.